Brief: Sangamo Therapeutics Q3 EPS USD -0.59

Sangamo Therapeutics

01/11/2023 20:01

Nov 01 (Reuters) - Sangamo Therapeutics Q3 operating expenses USD 115.8
million.
* Q3 revenue USD 9.398 million vs. IBES estimate USD 10.4 million
* Q3 net income USD -104.163 million
* Q3 adjusted operating expenses USD 64.8 million
* Q3 operating income USD -106.408 million